Related references
Note: Only part of the references are listed.Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
Jonathan M. Kocarnik et al.
JAMA ONCOLOGY (2022)
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Simon Eschweiler et al.
NATURE (2022)
T-cell-based breast cancer immunotherapy
Karolina Pilipow et al.
SEMINARS IN CANCER BIOLOGY (2021)
Immunomodulation by targeted anticancer agents
Giulia Petroni et al.
CANCER CELL (2021)
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage et al.
FRONTIERS IN IMMUNOLOGY (2021)
Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells
Nirupama D. Verma et al.
SCIENTIFIC REPORTS (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis
Yiqun Han et al.
CURRENT PROBLEMS IN CANCER (2020)
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
Pauline du Rusquec et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
Andres Forero-Torres et al.
BLOOD (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors
Ee Lyn Lim et al.
JCI INSIGHT (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Paule Augereau et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Rasha Abu Eid et al.
CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
Shamim Ahmad et al.
CANCER RESEARCH (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2016)
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
Valentina Sini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
Rasha Abu-Eid et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Isolation of CD4+CD25+ regulatory T cells for clinical trials
P Hoffmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
PI3K in lymphocyte development, differentiation and activation
K Okkenhaug et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Share Paper
